Evaluation of the Efficacy of Kallikrein Inhibition by Lanadelumab for Patients With Bradykinin Angioedema: a Cohort Study
Latest Information Update: 14 Feb 2022
At a glance
- Drugs Lanadelumab (Primary)
- Indications Hereditary angioedema
- Focus Therapeutic Use
- Acronyms KALAN
- 28 Oct 2020 New trial record